Federal Register / Vol. 63, No. 80 / Monday, April 27, 1998 / Notices 20641

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer.

[FR Doc. 98–11112 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Use of Short WAP Promoter

in Mammary Tissue of Transgenic

Animals

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 08/246,259, filed

May 19, 1994, entitled ‘‘Transgenic

Animals Secreting Desired Proteins Into

Milk’’ to the American Red Cross having

a place of business in Rockville,

Maryland. The patent rights in these

inventions have been assigned to the

United States of America.

The field of use will be the use of the

invention for the production in

transgenic animals of factor VIII, factor

IX, fibrinogen, Protein C, and von

Willebrand factor.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before June

26, 1998 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Leopold J. Luberecki, Jr.,

J.D., Technology Licensing Specialist,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Box 13, Rockville, MD

20852–3804; Telephone: (301) 496–

7735, ext. 223; Facsimile: (301) 402–

0220. A signed Confidential Disclosure

Agreement will be required to receive

copies of the patent application.

SUPPLEMENTARY INFORMATION: The patent

application claims a transgenic, nonhuman mammal containing a gene that

encodes a protein, the gene being under

the transcriptional control of a

mammalian milk protein promoter

which does not naturally control the

transcription of the gene, the DNA

sequence further including DNA

enabling secretion of the protein. The

promoter can be that of a milk serum

protein, which includes the whey acid

protein (WAP) or a casein protein. The

invention permits the production of a

desired protein in a living domesticated

mammal, which is capable not only of

producing the desired protein, but

preferably of passing on the ability to do

so to its female offspring. The present

invention specifically includes an

exogenous DNA sequence that has the 5′

2.6 kb promoter fragment of the mouse

whey acid protein (WAP) gene.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–11115 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Use of Long WAP Promoter in

Mammary Tissue of Transgenic

Animals

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 07/943,246, filed

September 10, 1992, entitled

‘‘Expression of Active Protein C in

Mammary Tissue of Transgenic Animals

Using a Long WAP Promoter’’ to

Genzyme Transgenics Corporation,

having a place of business in

Framingham, Massachusetts. The patent

rights in these inventions have been

assigned to the United States of

America.

The field of use will be the use of the

invention for the production in

transgenic animals of alpha interferon,

alpha-1 proteinase inhibitor,

angiogenin, antithrombin III, beta

interferon, calf intestine alkaline

phosphatase, cystic fibrosis

transmembrane regulator, Factor X,

glutamic acid decarboxylase, human

growth hormone, human serum

albumin, insulin, lactoferrin, longer

acting tissue plasminogen activator,

myelin basic protein, pro-insulin,

prolactin, soluble CD4 HIV receptor,

tissue plasminogen activator, the

recombinant monoclonal antibody

against Lewis Y antigen designated

BR96, and the monoclonal antibody

designated CTLA4 Ig.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before June

26, 1998 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Leopold J. Luberecki, Jr.,

J.D., Technology Licensing Specialist,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Box 13, Rockville, MD

20852–3804; Telephone: (301) 496–

7735, ext. 223; Facsimile: (301) 402–

0220. A signed Confidential Disclosure

Agreement will be required to receive

copies of the patent application.

SUPPLEMENTARY INFORMATION: The patent

application claims a transgenic, nonhuman mammal containing an

exogenous DNA sequence that has the 5′

4.2 kb promoter fragment of the mouse

whey acid protein (WAP) gene, or a

variant thereof, operably linked to a

DNA sequence encoding an active

polypeptide and a signal peptide, such

that the WAP promoter is specifically

active in mammary cells and the signal

peptide is effective in directing the

secretion of the polypeptide into the

milk of the transgenic animal. The

invention goes on to describe a process

for the production of the polypeptide by

using the promoter and the signal

peptide to produce the desired

polypeptide in the milk of the
20642 Federal Register / Vol. 63, No. 80 / Monday, April 27, 1998 / Notices

transgenic animal, collecting the milk,

and isolating the polypeptide therefrom.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–11113 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Use of Short WAP Promoter

in Mammary Tissue of Transgenic

Animals

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 08/246,259, filed

May 19, 1994, entitled ‘‘Transgenic

Animals Secreting Desired Proteins Into

Milk’’ to Genzyme Transgenics

Corporation, having a place of business

in Framingham, Massachusetts. The

patent rights in these inventions have

been assigned to the United States of

America.

The field of use will be the use of the

invention for the production in

transgenic animals of alpha interferon,

alpha-1 proteinase inhibitor,

angiogenin, antithrombin III, beta

interferon, calf intestine alkaline

phosphatase, cystic fibrosis

transmembrane regulator, Factor X,

glutamic acid decarboxylase, human

growth hormone, human serum

albumin, insulin, longer acting tissue

plasminogen activator, myelin basic

protein, pro-insulin, prolactin, tissue

plasminogen activator, soluble CD4 HIV

receptor, the recombinant monoclonal

antibody against Lewis Y antigen

designated BR96, and the monoclonal

antibody designated CTLA4 Ig.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before June

26, 1998 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Leopold J. Luberecki, Jr.,

J.D., Technology Licensing Specialist,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Box 13, Rockville, MD

20852–3804; Telephone (301) 496–7735,

ext. 223; Facsimile: (301) 402–0220. A

signed Confidential Disclosure

Agreement will be required to receive

copies of the patent application.

SUPPLEMENTARY INFORMATION: The patent

application claims a transgenic, nonhuman mammal containing a gene that

encodes a protein, the gene being under

the transcriptional control of a

mammalian milk protein promoter

which does not naturally control the

transcription of the gene, the DNA

sequence further including DNA

enabling secretion of the protein. The

promoter can be that of a milk serum

protein, which includes the whey acid

protein (WAP) or a casein protein. The

invention permits the production of a

desired protein in a living domesticated

mammal, which is capable not only of

producing the desired protein, but

preferably of passing on the ability to do

so to its female offspring. The present

invention specifically includes an

exogenous DNA sequence that has the 5’

2.6 kb promoter fragment of hte mouse

whey acid protein (WAP) gene.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–11114 Filed 4–24–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Spectroscopic Imaging

Device Employing Imaging Quality

Spectral Filters

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of an exclusive license to

practice the invention embodied in U.S.

Patent Number 5,377,003 and U.S.

Patent Application Number 08/996,497,

entitled ‘‘Spectroscopic Imaging Device

Employing Imaging Quality Spectral

Filters’’, to Spectral Dimensions, Inc.,

having a place of business in Boston,

Massachusetts. The patent rights in this

application have been assigned to the

United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7 and may be

limited to the field of use of veterinary

and human clinical diagnosis.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before June

26, 1998 will be considered.

ADDRESSES: Requests for a copy of this

patent application, inquiries, comments,

and other materials relating to the

contemplating license should be

directed to: John Fahner-Vihtelic, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: 301/

496–7735 ext. 270; Fax: 301/402–0220;

e-mail: jf36z@nih.gov. A signed

Confidentiality Agreement will be

required to review copies of the patent

application.